AI Bits articles

Patients want to be told when AI is used in their care, and a study proposes three levels of telling, The Friday Ethics Desk, 2026-11-06

Gemini 4 Carbon, OpenAI's $20B target, Anthropic's junk rating, a backdoored extension, The Monday Recap, 2026-11-02

An AI agent that never denies a prior authorization: where does the accountability sit?, The Friday Ethics Desk, 2026-10-30

Pathos AI raises $237M, with Bristol Myers and Tempus, to bring its trial-planning model to Alzheimer's, The Wednesday Pharma R&D, 2026-10-28

OpenAI's $30B raise, DeepSeek's $15B, a chatbot election study, Kimi K3.1 Pro, Lycia's IPO, The Monday Recap, 2026-10-26

When a medical AI gives wrong advice, who is responsible? The AMA asks the FDA, The Friday Ethics Desk, 2026-10-23

An AI that prepares oncologists for first consultations, tested by nine clinicians on 33 cases, The Wednesday Pharma R&D, 2026-10-21

Meta's first frontier model, Anthropic's $16.8B quarter, a Replit switch and Iambic's $150M IPO, The Monday Recap, 2026-10-19

When AI rewrites medical texts for patients, a new study finds about half the knowledge gets lost, The Friday Ethics Desk, 2026-10-16

An AI that listens to clinic visits and grades side effects, tested on 31 prostate cancer patients, The Wednesday Pharma R&D, 2026-10-14

A $20B revenue correction, a non-text model at $7.5B, Mistral's return and a $4B neocloud round, The Monday Recap, 2026-10-12

An AI agent mentioned a private message, and Apple tightened its access rules, The Friday Ethics Desk, 2026-10-09

An AI checker for clinical trial reports, built on 119 reporting questions, The Wednesday Pharma R&D, 2026-10-07

A faster Sonnet, an $8.2B chip-and-world-model deal, a cyber-only Gemini and a biology lab loop, The Monday Recap, 2026-10-05

Should an AI make the first cut on research funding?, The Friday Ethics Desk, 2026-10-02

Vaccines that last two months at 37 °C, and the AI that found them in a month, The Wednesday Pharma R&D, 2026-09-30

A price war, a $2B bet on nature-made drugs, and doctors who miss most hallucinations, The Monday Recap, 2026-09-28

OpenAI Bought the Layer That Runs the Drug Program, by Matteo Favilli, Oct 2026

Europe Has an AI Strategy. The Budget Is Another Story., by Matteo Favilli, May 2026

AI Just Rewrote the Rules of Drug Approval, by Matteo Favilli, May 2026

OpenAI Just Confirmed the Direction. Twice in One Week., by Matteo Favilli, Apr 2026

Claude Design Dropped. The Capabilities Are Insane., by Matteo Favilli, Apr 2026

What the Stanford AI Index 2026 Actually Says, by Matteo Favilli, Apr 2026

Anthropic Paid $400M for a Problem, by Matteo Favilli, Apr 2026

AI's Memory Problem, and Google's Fix, by Matteo Favilli, Mar 2026

A 20-Year-Old Built This in 10 Days. Then It Got Complicated., by Matteo Favilli, Mar 2026

The Chat Interface Was Just the Lobby, by Matteo Favilli, Mar 2026

Most Enterprise AI Projects Don't Fail Because the Tech Is Bad, by Matteo Favilli, Mar 2026

Independent, unfunded, unaffiliated

AI Bits

AI, work, and whether the money actually moves

Sources under everything

AI stocksUS markets

Market data by TradingView

AI Labs & LLMs

What Anthropic, OpenAI, Google, Meta and Mistral actually shipped. Sources only, no commentary.

AI, Pharma & Life Sciences

AI in pharma, biotech, medtech and the clinic. Regulators and peer-reviewed journals first.

Funding & Deals

Rounds, acquisitions and listings this week, with the number up front.

by Matteo Favilli Key reports

My own pieces on AI, work and where the money actually moves. Written, not aggregated.

00 pieces